0001209191-20-013025.txt : 20200226 0001209191-20-013025.hdr.sgml : 20200226 20200226163254 ACCESSION NUMBER: 0001209191-20-013025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kewalramani Reshma CENTRAL INDEX KEY: 0001735944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20656252 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-24 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001735944 Kewalramani Reshma C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 EVP and CMO Common Stock 2020-02-24 4 F 0 2898 239.23 D 30260 D Common Stock 2020-02-25 4 S 0 893 229.72 D 29367 D Common Stock 2020-02-25 4 S 0 450 230.88 D 28917 D Common Stock 2020-02-25 4 S 0 440 232.35 D 28477 D Common Stock 2020-02-25 4 S 0 660 234.41 D 27817 D Common Stock 2020-02-25 4 S 0 340 235.36 D 27477 D Common Stock 2020-02-25 4 S 0 320 236.71 D 27157 D Common Stock 2020-02-25 4 S 0 420 238.28 D 26737 D Common Stock 2020-02-25 4 S 0 111 239.13 D 26626 D Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.17). Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $230.88 (range $230.48 to $231.38). Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.14 to $233.08). Open market sales reported on this line occurred at a weighted average price of $234.41 (range $233.90 to $234.80). Open market sales reported on this line occurred at a weighted average price of $235.36 (range $235.13 to $235.56). Open market sales reported on this line occurred at a weighted average price of $236.71 (range $236.31 to $237.24). Open market sales reported on this line occurred at a weighted average price of $238.28 (range $238.01 to $238.54). Open market sales reported on this line occurred at a weighted average price of $239.13 (range $239.13 to $239.14). /s/ Omar White, Attorney-in-Fact 2020-02-26